Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (USFDA) for Clindamycin Phosphate Gel USP, 1%, the generic version of Cleocin T1
Gel, 1%, of Pharmacia & Upjohn.
According to IQVIATM sales data for the 12 month period ending December 2020, the Cleocin T Gel, 1% market achieved annual sales of approximately $73.8 million.
Glenmark's current portfolio consists of 169 products authorized for distribution in the U.S. marketplace and 42 ANDA's pending approval with the USFDA.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
